Amgen's third-quarter 2024 earnings call highlighted several positive factors that are likely to have a positive impact on the stock price in the short term:

- **Strong Revenue and Earnings Growth**: Total revenues increased by 23% to $8.5 billion, and GAAP EPS increased by 62%, driven by robust sales growth and higher revenues[1][4][5].
- **Product Performance**: Multiple products, including Repatha, TEZSPIRE, BLINCYTO, and EVENITY, showed double-digit sales growth, indicating strong market performance across various therapeutic areas[1][4].
- **Pipeline Advances**: Significant progress in the clinical pipeline, including the initiation of Phase II and III studies for several promising medicines like MariTide, xaluritamig, and UPLIZNA, positions Amgen well for long-term growth[1][3][4].
- **Financial Health**: The company generated $3.3 billion in free cash flow, reduced principal debt by $2.5 billion, and maintained a strong balance sheet, indicating solid financial management[1][4].
- **Guidance and Outlook**: Amgenâ€™s guidance for 2024 remains positive, with projected total revenues in the range of $33.0 billion to $33.8 billion and non-GAAP EPS between $19.20 and $20.00, which aligns with investor expectations[1][4].

Given these positive factors, including strong financial performance, advancing pipeline, and solid financial health, the stock is likely to experience a positive impact in the short term.

**Rating: 2**